Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29205778 | 0.81 | USP2 (0.45) | NAMPTEPHX1HPGDEPHX2SMN1; SMN2 | |
| SCHEMBL1003106 | 0.79 | EPHX2 (0.46) | NAMPTEPHX1CNR2HPGDEPHX2 | |
| SCHEMBL22576321 | 0.79 | KDM4E (0.45) | KDM4EPKMNAMPTFPR3FPR2 | |
| SCHEMBL1820480 | 0.77 | NR1H2 (0.43) | KDM4EPKMEPHX1NR1H2HPGD | |
| SCHEMBL1586974 | 0.75 | EPHX2 (0.43) | EPHX1EPHX2JAK2JAK1SMN1; SMN2 | |
| SCHEMBL343979 | 0.75 | USP2 (0.47) | EPHX1NR1H2HPGDEPHX2SMN1; SMN2 | |
| SCHEMBL18319088 | 0.74 | EPHX2 (0.42) | KDM4ENAMPTEPHX1CNR2EPHX2 | |
| SCHEMBL5573225 | 0.74 | KDM4E (0.63) | KDM4EPKMEPHX1KDM1AHPGD | |
| SCHEMBL18418212 | 0.74 | USP2 (0.50) | EPHX1NR1H2HPGDEPHX2SMN1; SMN2 | |
| SCHEMBL19625229 | 0.74 | EPHX2 (0.39) | NAMPTEPHX2SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727378-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | KDM4E 4298/4885PKM 1825/4885NAMPT 310/4885 |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | KDM4E 4298/4885PKM 1825/4885NAMPT 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.